<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><META HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 14 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
{mso-style-priority:99;
mso-style-link:"Plain Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.PlainTextChar
{mso-style-name:"Plain Text Char";
mso-style-priority:99;
mso-style-link:"Plain Text";
font-family:"Calibri","sans-serif";}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri","sans-serif";}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-US link=blue vlink=purple><div class=WordSection1><p class=MsoPlainText><o:p> </o:p></p><p class=MsoPlainText>Googled bexarotene therapeutic dose, found it was 75 mg per day (for cancer patients), then went looking for sources, found this:<o:p></o:p></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'><a href="http://www.drugstore.com/targretin/75mg-capsules/qxn62856060210">http://www.drugstore.com/targretin/75mg-capsules/qxn62856060210</a><o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'>This site says Targretin's patents don't expire until 2016, but I don't know if it contains other stuff besides bexarotene:<o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'><a href="http://www.medcitynews.com/2011/10/generic-cancer-drug-from-banner-aims-to-take-on-eisais-targretin/">http://www.medcitynews.com/2011/10/generic-cancer-drug-from-banner-aims-to-take-on-eisais-targretin/</a><o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'>This site says Banner Pharmacaps Inc has applied for an FDA fast track for a generic version of Targretin, back last October.<o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'><a href="http://banpharm.com/newsview.cfm/pID/31">http://banpharm.com/newsview.cfm/pID/31</a><o:p></o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText><span style='color:black'><o:p> </o:p></span></p><p class=MsoPlainText>spike <o:p></o:p></p></div></body></html>